Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 7,623 matching trials from the live ClinicalTrials.gov search.
Conditions
Cardiac Surgery
Interventions
teprasiran, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GW433908, ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
4 Weeks to 2 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo-matching Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
137
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 112 more
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Placebo, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
60
States / cities
Bakersfield, California • Chula Vista, California • La Jolla, California + 43 more
Conditions
Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions
Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
54
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma, Recurrent Metastatic Melanoma
Interventions
Anti-PD-L1 Monoclonal Antibody IMC-001, Punch Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of a Daily Disposable Silicone Hydrogel Multifocal Contact Lens in Myopes and Hyperopes

NCT05222880
Conditions
Visual Acuity
Interventions
JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
12
States / cities
Jacksonville, Florida • Maitland, Florida • Tallahassee, Florida + 8 more
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
76
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 66 more
Completed Not applicable Interventional

pRESET for Occlusive Stroke Treatment

NCT03994822
Conditions
Brain Diseases, Cardiovascular Diseases, Central Nervous System Diseases, Cerebrovascular Disorders, Ischemia, Nervous System Diseases, Pathologic Processes, Stroke, Ischemic, Stroke, Acute, Vascular Diseases
Interventions
Mechanical Thrombectomy using the pRESET Thrombectomy device, Mechanical Thrombectomy using the Solitaire Revascularization Device
Device
Lead sponsor
phenox Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Scottsdale, Arizona • Santa Monica, California • Coral Gables, Florida + 15 more
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
efgartigimod PH20 SC in stage B, placebo in stage B
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
127
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 117 more
Terminated Phase 2 Interventional Results available

Alvocidib Biomarker-driven Phase 2 AML Study

NCT02520011
Conditions
Acute Myeloid Leukemia
Interventions
Alvocidib, Cytarabine, Mitoxantrone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
26
States / cities
Scottsdale, Arizona • Los Angeles, California • San Diego, California + 23 more
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
carboplatin, lomustine, procarbazine hydrochloride, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 9 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
179
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 141 more
Conditions
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
61
States / cities
Arcadia, California • Bakersfield, California • Beverly Hills, California + 57 more
Conditions
Basal Cell Carcinoma
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
80
States / cities
Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 69 more
Conditions
HIV Infections, Adherence, Medication
Interventions
Tech2Check
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Conditions
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma, Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Nasopharyngeal Carcinoma AJCC v8
Interventions
Carboplatin, Cisplatin, Gemcitabine, Nivolumab, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
322
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 204 more
Conditions
Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
113
States / cities
Birmingham, Alabama • Downey, California • Duarte, California + 90 more
Conditions
Diabetes Mellitus, Type 2
Interventions
MK-2828, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
24 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
11
States / cities
Chula Vista, California • Glendale, California • Hallandale, Florida + 8 more
Active, not recruiting Not applicable Interventional

AMPLATZER PFO Occluder Post Approval Study

NCT03309332
Conditions
Stroke, Patent Foramen Ovale
Interventions
AMPLATZER™ PFO Occluder
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 60 Years
Enrollment
1,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 63 more
Conditions
Alcohol-related Liver Disease
Interventions
NNC0194-0499, Semaglutide, NNC0194-0499 placebo, Semaglutide placebo (Group A), Cagrilintide + semaglutide, Cagrilintide, Cagrilintide placebo, Semaglutide placebo (Group B)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Chandler, Arizona • Tucson, Arizona • Lancaster, California + 23 more
Conditions
Vasomotor Symptoms (VMS)
Interventions
MT-8554
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
53
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 46 more